Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03XTC
|
||||
| Former ID |
DAP000304
|
||||
| Drug Name |
Esmolol
|
||||
| Synonyms |
ASL 8052-001; Brevibloc (TN); Esmolol (INN); Esmolol [INN:BAN]; Methyl p-[2-hydroxy-3-(isopropylamino)propoxy]hydrocinnamate; Methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate; Methyl 3-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]propanoate; Methyl 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)benzenepropanoate; Methyl 3-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]propanoate; Methyl 3-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}propanoate; Benzenepropanoic acid, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, methyl ester; (+-)-Esmolol; (+-)-methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Acute supraventricular tachycardia [ICD9: 427.0, 427.89; ICD10:I47.1] | Approved | [1], [2] | ||
| Therapeutic Class |
Antihypertensive Agents
|
||||
| Company |
Bedford Laboratories
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C16H25NO4
|
||||
| InChI |
InChI=1S/C16H25NO4/c1-12(2)17-10-14(18)11-21-15-7-4-13(5-8-15)6-9-16(19)20-3/h4-5,7-8,12,14,17-18H,6,9-11H2,1-3H3
|
||||
| InChIKey |
AQNDDEOPVVGCPG-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 103598-03-4
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
9194, 7435390, 7979187, 8186499, 14825011, 43117267, 46506146, 48415954, 49881073, 50068830, 50307609, 57313969, 85209983, 92309302, 92711342, 96024612, 99313645, 103203672, 104319031, 117553531, 124896652, 124896653, 126422058, 126630958, 126683075, 126684165, 127444743, 134337616, 135018086, 135060484, 137252284, 137862731, 141092871, 152100153, 160963535, 162179020, 163134401, 163353820, 176484552, 178103753, 179151222, 179500095, 184675752, 211535411, 223653372, 223682206, 223837113, 226395749, 241162565, 250133519
|
||||
| SuperDrug ATC ID |
C07AB09
|
||||
| SuperDrug CAS ID |
cas=081147924
|
||||
| Target and Pathway | |||||
| Target(s) | Beta-1 adrenergic receptor | Target Info | Antagonist | [3] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| cGMP-PKG signaling pathway | |||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Endocytosis | |||||
| Adrenergic signaling in cardiomyocytes | |||||
| Gap junction | |||||
| Salivary secretion | |||||
| Dilated cardiomyopathy | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Beta1 adrenergic receptor signaling pathway | |||||
| PathWhiz Pathway | Muscle/Heart Contraction | ||||
| Reactome | Adrenoceptors | ||||
| G alpha (s) signalling events | |||||
| WikiPathways | Monoamine GPCRs | ||||
| Calcium Regulation in the Cardiac Cell | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Endothelin Pathways | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7178). | ||||
| REF 3 | Beta-1 selective adrenergic antagonist landiolol and esmolol can be safely used in patients with airway hyperreactivity. Heart Lung. 2009 Jan-Feb;38(1):48-55. Epub 2008 Sep 11. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.